[August 14, 2015]

Research and Markets: Cystic Fibrosis Forecast 2015-2025 - Delivery of More Accurate Information for Clinical Trials in Study Sizing and Realistic Patient Recruitment for Various Countries.

Research and Markets (http://www.researchandmarkets.com/research/crkcsz/epiomic) has announced the addition of the "Epiomic Epidemiology Series: Cystic Fibrosis Forecast in 9 Major Markets 2015-2025" report to their offering.

Epiomic Epidemiology Series: 9 Major Markets

This report provides the current prevalent population for CF across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort.

Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of CF. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

This report is built using data and information souced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies.

Reason to Purchase:

• Able to quantify patient populations in global CF's market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of CF and identify patient segments with high potential.
• Provide a level of understanding on the impact from specific co-morbid conditions on CF's prevalent population.

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors and Prevention

4. Diagnosis of the Disease

5. Variation by Geography/ Ethnicity

6. Disease Prognosis (News - Alert) and Clinical Course

7. Key Co-Morbid Conditions / Features associated with the Disease

8. Methodology for Quantification of Patient Numbers

9. Top-Line Prevalence for Cystic Fibrosis

10. Abbreviations used in the Report

11. Other Publications

12. Online Patient-Based Databases

13. Patient-Based Offering

14. Online Pricing Data and Platforms

15. References

16. Appendix

For more information visit http://www.researchandmarkets.com/research/crkcsz/epiomic

View source version on businesswire.com: http://www.businesswire.com/news/home/20150814005098/en/

[ Back To TMCnet.com's Homepage ]